Bicycle therapeutics announces expedited development plan for bt8009 in metastatic bladder cancer

Cambridge, england & boston--(business wire)--bicycle therapeutics (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the company will proceed with its plan to expedite development of bt8009 for metastatic bladder (urothelial) cancer following recent discussions with the u.s. food and drug administration (fda). the company has aligned with the fda on a phase 2/3 regist.
BCYC Ratings Summary
BCYC Quant Ranking